It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for people with obesity could cost it up to $70 million a year, covering up to 20% of eligible enrollees.

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep apnea in people with obesity. CNBC said Wednesday that the U.S. Centers for Medicare & Medicaid Services confirmed that Medicare drug plans can now cover Zepbound,